BRCA1 deficiencies cause breast, ovarian, prostate and other cancers, and render tumours hypersensitive to poly(ADPribose) polymerase (PARP) inhibitors. To understand the resistance mechanisms, we conducted whole-genome CRISPR-Cas9 synthetic-viability/resistance screens in BRCA1-deficient breast cancer cells treated with PARP inhibitors. We identified two previously uncharacterized proteins, C20orf196 and FAM35A, whose inactivation confers strong PARP-inhibitor resistance. Mechanistically, we show that C20orf196 and FAM35A form a complex, 'Shieldin' (SHLD1/2), with FAM35A interacting with single-stranded DNA through its C-terminal oligonucleotide/oligosaccharide-binding fold region. We establish that Shieldin acts as the downstream effector of 53BP1/RIF1/MAD2L2 to promote DNA double-strand break (DSB) endjoining by restricting DSB resection and to counteract homologous recombination by antagonizing BRCA2/RAD51 loading in BRCA1-deficient cells. Notably, Shieldin inactivation further sensitizes BRCA1-deficient cells to cisplatin, suggesting how defining the SHLD1/2 status of BRCA1-deficient tumours might aid patient stratification and yield new treatment opportunities. Highlighting this potential, we document reduced SHLD1/2 expression in human breast cancers displaying intrinsic or acquired PARP-inhibitor resistance.
D NA double-strand breaks (DSBs) are highly cytotoxic cellular lesions that must be effectively and accurately repaired to maintain genome stability and prevent premature aging, neurodegeneration, immunodeficiency, cancer and other diseases [1] [2] [3] . In response to DSB detection, the apical kinases ATM, ATR and PRKDC (DNA-dependent protein kinase catalytic subunit) become activated and phosphorylate numerous substrates to initiate the cellular DNA damage response (DDR) 4 . The ensuing cascade of molecular DDR events, which are promoted by various post-translational modifications including protein phosphorylation, ubiquitylation, sumoylation and poly (ADP-ribosyl)ation, impacts on a myriad of cellular components, among other things leading to the assembly of DDR factors at DNA-damage sites, arrest or slowing of cell-cycle progression, and activation of DNA repair mechanisms 4, 5 . The two main types of DSB-repair pathway are non-homologous end-joining (NHEJ), which is active throughout the cell cycle, and homologous recombination (HR), which normally requires a sister chromatid as a template and hence only operates in the S and G2 phases of the cell cycle. DSB-repair pathway choice is partly determined by functional antagonism between the HR-promoting factor BRCA1 and NHEJ-promoting proteins such as TP53BP1 (53BP1), RIF1 and MAD2L2 (REV7) [6] [7] [8] [9] [10] [11] [12] [13] .
Inherited or acquired mutations in the BRCA1 or BRCA2 genes that result in protein loss or a mutant BRCA1/2 protein cause breast, ovarian, prostate and other cancers, and render tumours hypersensitive to poly(ADP-ribose) polymerase (PARP)-inhibitor drugs such as olaparib [14] [15] [16] [17] . Unfortunately, intrinsic or acquired PARP-inhibitor resistance frequently leads to a lack of response or to patient relapse and tumour regrowth 15, 18 . In the clinic, the most common PARP-inhibitor resistance mechanisms reported to date are restoration of BRCA1/2 expression or function. Notably, 53BP1 expression is lost in various triple-negative breast cancers 7 , which may account for certain clinically relevant examples of PARPinhibitor resistance. Nevertheless, the mechanisms driving PARPinhibitor resistance in a large proportion of BRCA1/2-deficient tumours remain unexplained 18, 19 .
To systematically survey for genetic mechanisms of PARPinhibitor resistance, we conducted whole-genome CRISPR-Cas9 synthetic-viability/resistance screens in human BRCA1-deficient breast cancer cells treated with PARP inhibitors. In addition to identifying known resistance factors such as 53BP1, RIF1 and MAD2L2 loss [6] [7] [8] [9] [10] [11] [12] [13] , we identified two previously uncharacterized proteins, C20orf196 and FAM35A, whose inactivation confers PARP-inhibitor resistance to BRCA1-deficient cells. Our ensuing work led us to define the 'Shieldin' (SHLD1 C20orf196 /SHLD2 FAM35A ) complex, which promotes NHEJ by serving as the downstream effector of 53BP1, RIF1 and MAD2L2, restricts DSB resection, and counteracts HR in BRCA1deficient cells by antagonizing replacement of replication protein A (RPA) with BRCA2 and RAD51 on resected single-stranded DNA (ssDNA). Finally, we report that SHLD1 C20orf196 /SHLD2 FAM35A loss confers hypersensitivity to the DNA-crosslinking agent cisplatin, and that reduced SHLD1 C20orf196 or SHLD2 FAM35A expression is associated with evolution of PARP-inhibitor resistance in a patient-derived BRCA1-deficient breast cancer xenograft model and in BRCA1mutant cancers displaying intrinsic PARP-inhibitor resistance.
Results

FAM35A or C20orf196 loss suppresses PARP-inhibitor sensitivity of BRCA1-mutant cells.
To systematically explore genetic mechanisms imparting PARP-inhibitor resistance, we carried out genome-wide CRISPR-Cas9 gene-inactivation screens with the GeCKO library 20 in the BRCA1-mutant breast cancer cell line SUM149PT treated in parallel with the PARP inhibitors olaparib, talazoparib (BMN673) or AZD2461 (Fig. 1a,b and Supplementary  Fig. 1a-c) . In addition to identifying the known resistance genes TP53BP1, RIF1 and MAD2L2, whose products form a complex 21 , we identified several new suppressor candidates (Supplementary Table 1 and Supplementary Fig. 1d,e ). These included DYNLL1, a known 53BP1 interaction partner 22 , and TEN1, a component of the CST telomere-capping complex (CTC1/STN1/TEN1) that also promotes telomere DNA replication 23 . In our ensuing studies, however, we focused on the uncharacterized proteins FAM35A and C20orf196, which collectively received the highest scores from our screens ( Fig. 1b and Supplementary Table 1 ). Thus, by carrying out short-interfering RNA (siRNA) mediated mRNA silencing in non-transformed, human telomerase reverse transcriptase-immortalized retinal pigment epithelial 1 (RPE1) cells ( Supplementary Fig. 1f ), we established that, as for 53BP1 loss 7 , depletion of FAM35A or C20orf196 markedly suppressed PARP-inhibitor sensitivity caused by BRCA1 inactivation while having no discernible effect in BRCA1-proficient cells ( Fig. 1c and Supplementary Fig. 1g ). This conclusion was independently confirmed by de novo CRISPR-Cas9 gene editing, with FAM35A or C20orf196 inactivation alleviating the olaparib hypersensitivity of BRCA1-deficient cells in a manner counteracted by the reintroduction of wild-type FAM35A or C20orf196 (Fig. 1d,e and Supplementary Fig. 1h ; as shown in Supplementary Fig. 1i , these effects did not reflect altered cell-cycle profiles).
FAM35A/C20orf196 complex interacts with and acts downstream of 53BP1/RIF1/MAD2L2. Sequence analyses indicated that FAM35A and C20orf196 are well conserved in vertebrates. Moreover, structure prediction modelling (RaptorX; http://raptorx.uchicago.edu/) revealed that FAM35A harbours a disordered N terminus and an ordered C-terminal region containing three oligonucleotide/oligosaccharide-binding (OB) folds, with the last C-terminal OB fold/FAM domain containing a CXXC-type zinc finger motif ( Fig. 2a ). Notably, this organization is highly similar to those of the RPA1 subunit of ssDNA binding protein RPA and the CTC1 subunit of the CST complex that also binds ssDNA 23 . In this regard, we noted that while the C20orf196 N terminus (residues 1-70) is predicted to be intrinsically disordered, its C-terminal part is more structured and may harbour one-or two-winged helix (WH) domains ( Fig. 2a ) similar to those in the yeast CST subunit Stn1 23, 24 , suggesting that C20orf196 and Stn1 might play analogous or complementary roles.
By combining cellular co-localization and co-immunoprecipitation experiments, we established that FAM35A and C20orf196 directly interact in a manner that is mainly, but not exclusively, mediated by the FAM35A OB3/FAM domain (Fig. 2b,c and Supplementary Fig. 2a,b ). Because loss of FAM35A or C20orf196 had similar effects to loss of 53BP1/RIF1/MAD2L2 in BRCA1deficient cells, we tested for possible interactions between these factors. Thus, via co-immunoprecipitation and mass spectrometry (MS) studies, we found that both C20orf196 and FAM35A interact with MAD2L2, the most distal factor of the 53BP1/RIF1/MAD2L2 axis mediating PARP-inhibitor sensitivity in BRCA1-deficient cells [6] [7] [8] [9] [10] [11] [12] [13] (Fig. 2d and Supplementary Fig. 2c ).
Many DDR proteins accumulate at DSB sites within ionizing radiation (IR)-induced nuclear foci (IRIF) 5 . We established that both FAM35A and C20orf196 formed IRIF, and by live-cell imaging studies found that the proteins were also recruited to localized DNA-damage sites induced by laser micro-irradiation ( Supplementary Fig. 2d ). Furthermore, we determined by confocal and super-resolution microscopy that FAM35A co-localized with the established DSB markers phosphorylated histone H2AFX 25 (γ H2AX) and 53BP1 26 (Fig. 2e ,f and Supplementary Fig. 2e ). Notably, siRNA/shRNA-depletion experiments established that while 53BP1 IRIF and MAD2L2 levels and IRIF were not significantly impaired by FAM35A or C20orf196 depletion ( Supplementary Fig. 2f -h), IRIF formation by FAM35A and C20orf196 required 53BP1, RIF1 and MAD2L2 but not PTIP ( Fig. 2e and Supplementary Fig. 3a -c; note that the total levels of green fluorescent protein (GFP)tagged FAM35A/C20orf196 were minimally affected by 53BP1/ RIF1/MAD2L2 depletion). We also established that C20orf196 IRIF were almost totally abrogated by FAM35A depletion, while C20orf196 depletion reduced but did not abolish FAM35A IRIF ( Fig. 2e ). In addition, FAM35A formed nuclear foci when cells were treated with the DNA topoisomerase I inhibitor camptothecin (CPT; Supplementary Fig. 3d ). Significantly, the FAM35A N terminus was necessary and sufficient for its IRIF formation; these IRIF depended on 53BP1, RIF1, MAD2L2 and C20orf196, and this region could be co-immunoprecipitated with MAD2L2 ( Fig. 2f ,g and Supplementary Fig. 3e ,f). Collectively, these findings indicated that FAM35A and C20orf196 act as downstream components of 53BP1/RIF1/MAD2L2 molecular assembly 21 at DSB sites.
FAM35A and C20orf196 promote NHEJ. As 53BP1, RIF1 and MAD2L2 promote NHEJ 6-13 , we tested whether FAM35A and C20orf196 fulfil a similar role. Indeed, as for depletion of the NHEJ factor XRCC4, siRNA depletion of 53BP1, FAM35A or C20orf196 impaired NHEJ, as measured by random integration of plasmid DNA into chromosomes 27 (Fig. 3a ). In addition, FAM35A or C20orf196 depletion conferred IR hypersensitivity to both human and mouse cells ( Fig. 3b and Supplementary Fig. 4a ). 53BP1 and associated factors promote NHEJ-mediated class-switch recombination (CSR) at the immunoglobulin heavy-chain locus, a process that allows B lymphocytes to change antibody production from one type to another 28 . By CRISPR-Cas9 gene editing in mouse CH12F3 (CH12) B lymphocytes 29 , we established that, as for 53BP1/RIF1/ MAD2L2 inactivation 6, 8, [10] [11] [12] 30, 31 , loss of FAM35A or C20orf196 markedly reduced CSR (Fig. 3c,d and Supplementary Fig. 4b-d ). Furthermore, analysis of metaphase chromosomal spreads of such cells revealed that FAM35A or C20orf196 inactivation led to chromosomal breaks and translocations symptomatic of aberrant CSR 32 (Fig. 3e ,f; note from Supplementary Fig. 4e ,f that CSR effects were not associated with defects in cell proliferation, or in Aid or germline Sα switch region transcription). a, Schematic of screen procedure. MOI, multiplicity of infection; PARPi, PARP-inhibitor. b, MAGeCK analysis of guide enrichments following specified drug treatments; false discovery rate (FDR) of 0.1 indicated by dotted line; n = 3 technical replicates per drug treatment. c, siRNA-mediated verification of hits in clonogenic survival assays; lower panels show area under the curve (AUC); n = 3 independent experiments. d, De novo Cas9-mediated knockout (ko) verification and complementation for FAM35A in clonogenic survival assays (multiple ko clones are shown in AUC); n = 4 independent experiments except FAM35Ako(#14) (n = 2), FAM35Ako(#40) (n = 3), BRCA1ko/FAM35Ako(#34) (n = 2) and BRCA1ko/FAM35Ako(#2) + FAM35A (n = 3). e, As in d but for C20orf196; n = 3 independent experiments except BRCA1ko/C20orf196ko + C20orf196 (n = 2). In c-e, bars represent mean ± s.e.m., one-way analysis of variance (ANOVA); *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, NS, not significant (P ≥ 0.05). Individual data points are plotted over bars, and statistical source data including the precise P values are provided in Supplementary Table 5 .
FAM35A and C20orf196 antagonize DNA-end resection. To explore FAM35A and C20orf196 function further, we carried out assays in mouse cells harbouring a temperature-sensitive allele of the telomere-associated factor TRF2 (TRF2ts). TRF2ts inactivation at higher temperatures results in deprotected chromosome ends and causes NHEJ-mediated telomere fusions ( Fig. 4a ) 6, 33 . Strikingly, through the use of short-hairpin RNA (shRNA) mediated mRNA silencing, we found that such chromosome fusions were diminished by FAM35A or C20orf196 depletion, like that elicited by MAD2L2 depletion ( Fig. 4b and Supplementary Fig. 5a,b ). The impacts of 53BP1, RIF1 or MAD2L2 depletion in the TRF2ts system are connected to these factors counteracting DSB resection [6] [7] [8] [9] [10] [11] [12] [13] 34 . We thus explored whether FAM35A and C20orf196 might also have this function. Indeed, as for 53BP1/ RIF1/MAD2L2 inactivation [6] [7] [8] [9] [10] [11] [12] [13] 35 , loss of FAM35A or C20orf196 in human cells enhanced DSB-resection, as measured by RPA and ssDNA staining intensity in pre-extracted nuclei after treatment with CPT ( Fig. 4c -e; RPA1 kinetics at DNA damage sites induced by laser micro-irradiation were not altered by FAM35A or C20orf196 depletion, Supplementary Fig. 5c ). In line with this resection being mediated by canonical pathways, it was diminished by depletion of the resection promoting factors RBBP8 (CtIP) or BLM (bloom syndrome RecQ-like helicase, Fig. 4f ). Furthermore, we established that recruitment of BLM to sites of laser micro-irradiation was enhanced by FAM35A or C20orf196 depletion ( Fig. 4g ). Similarly, as shown for 53BP1 depletion in mouse cells 6 , FAM35A or C20orf196 depletion in such cells led to higher levels of the DNA-end resection marker, Ser4/8 phosphorylated RPA2, after IR treatment ( Fig. 4d ). Together with our other findings, these data established FAM35A and C20orf196 as crucial components of 53BP1/RIF1/MAD2L2-mediated chromosomal NHEJ, and suggested that their pro-NHEJ function is connected to limiting DSB resection.
FAM35A OB fold region interacts with ssDNA and promotes IR survival. Consistent with our prediction of structural similarity between FAM35A and RPA1, the FAM35A C terminus could be retrieved from cell extracts via interaction with a ssDNA oligonucleotide ( Fig. 5a ). Sequence alignment to RPA1 and structural modelling of FAM35A identified two Trp (W) residues predicted to be at the protein-ssDNA interface, based on analogous residues critical for RPA binding to ssDNA ( Fig. 5b and Supplementary Fig. 5d ). In accord with this prediction, we found, via electrophoretic gelmobility shift assays (EMSAs), that the bacterially expressed, purified FAM35A C-terminal region bound preferentially to ssDNA rather than double-stranded DNA ( Fig. 5c and Supplementary  Fig. 5e ), and ssDNA binding was reduced when the two Trp residues were mutated to Ala (W489/W640A; Fig. 5c ). Furthermore, while full-length FAM35A bearing these mutations (FAM35A W489/W640A ) still interacted with C20orf196 ( Supplementary Fig. 5f ) and formed IRIF in cells, these IRIF were consistently less pronounced than those of the wild-type FAM35A protein ( Fig. 5d ). This suggested that, following IRIF recruitment via its N-terminal region, the FAM35A C-terminal ssDNA binding region may allow further FAM35A recruitment, retention and/or stabilization. In addition, unlike the wild-type protein, FAM35A W489/W640A did not confer significant IR resistance when reintroduced into FAM35A null cells ( Fig. 5e ). In parallel studies, expression of the FAM35A C terminus did not complement the IR hypersensitivity of FAM35A null cells. Moreover, expression of the FAM35A N terminus rendered cells IR-hypersensitive, irrespective of whether they expressed endogenous FAM35A, implying that the N-terminal IRIF-forming domain of FAM35A may have a dominant-negative effect on NHEJ ( Fig. 5f ; overexpression of these FAM35A derivatives did not affect olaparib sensitivity in a wild-type background, Supplementary Fig. 5g ).
FAM35A and C20orf196 antagonize HR in BRCA1-deficient cells. PARP inhibitors generate replication-associated DNA lesions that require BRCA1-mediated HR for their effective repair 19 , and loss of 53BP1/RIF1/MAD2L2 partly restores the ability of BRCA1-deficient cells to repair such lesions [6] [7] [8] [9] [10] [11] [12] [13] . This has led to a model in which BRCA1 and 53BP1/RIF1/MAD2L2 play antagonistic roles in channelling DSBs towards HR or NHEJ, respectively. We thus speculated that BRCA1 might antagonize FAM35A/ C20orf196 action. Accordingly, both FAM35A and C20orf196 IRIF, but not 53BP1 IRIF, were significantly enhanced in number and intensity following BRCA1 but not BRCA2 depletion (Fig. 6a,b and Supplementary Fig. 6a,b ).
Collectively, our results suggested that FAM35A/C20orf196 act at the interface between the opposing functions of BRCA1 and 53BP1/RIF1/MAD2L2 to regulate DSB-repair pathway choice. Although this action could operate at least in part through control of DSB resection, which is misregulated and of slower kinetics in BRCA1-deficient cells 11, 36 , we reasoned that FAM35A/C20orf196 might also contribute to the severe defect in BRCA2-mediated RAD51 loading at DNA-damage sites in BRCA1-deficient cells 11, 35, 37 . Indeed, as for 53BP1 inactivation, loss of FAM35A or C20orf196 restored RAD51 IRIF formation in BRCA1-null cells ( Fig. 6c ). While exploring the mechanism for this effect, we found that elevated resection levels in FAM35A and C20orf196 knockout cells, as measured by RPA recruitment at DNA-damage sites, were still maintained in the absence of BRCA1 ( Supplementary  Fig. 6c,d ). Furthermore, FAM35A/C20orf196 depletion also alleviated the impaired recruitment of BRCA2 to DNA-damage sites in BRCA1-deficient cells ( Fig. 6d and Supplementary Fig.  6e ). Accordingly, studies with a cell-based chromosomal traffic light reporter (TLR) HR system 38, 39 established that FAM35A or C20orf196 depletion in BRCA1-deficient cells restored HR to levels similar to those acquired following 53BP1 depletion in this setting ( Fig. 6e and Supplementary 6f). In addition, removing FAM35A or C20orf196 rescued the spontaneous genomic instability phenotype of BRCA1 knockout cells ( Fig. 6f ). Building on our findings that the FAM35A N-terminal region largely mediates its localization to IRIF ( Fig. 2f and Supplementary Fig. 3e ,f), introducing the FAM35A N terminus, but not the C terminus, enhanced PARP-inhibitor sensitivity of BRCA1/FAM35A null cells ( Fig. 6g and Supplementary Fig. 6g ). Furthermore, FAM35A inactivation was epistatic to 53BP1 inactivation in relation to conferring PARP-inhibitor resistance in BRCA1 knockout cells ( Supplementary Fig. 6h ). Considering our findings together, we propose that C20orf196 and FAM35A be named SHLD1 and SHLD2, respectively, or collectively as the 'Shieldin complex' because it shields DSBs from inappropriate activities and promotes appropriate modes of DSB repair.
FAM35A/C20orf196 loss correlates with PARP-inhibitor resistance in cancers.
Having identified SHLD1 C20orf196 and SHLD2 FAM35A as mediating the PARP-inhibitor sensitivity of a BRCA1-deficient breast cancer cell line, we speculated that this might also apply in more physiological settings. Consequently, we employed a patient-derived xenograft (PDX) model of BRCA1-deficient breast cancer propagated in mice in the presence (cohort 2) or absence (cohort 1) of olaparib ( Fig. 7a ). The resistant tumour was further serially passaged into new hosts that were treated in the presence (cohort 4) or absence (cohort 3) of olaparib to confirm and sustain drug resistance ( Fig. 7a ; see also Supplementary Fig. 7a ). The tumours were then harvested and subjected to whole-genome RNA-sequencing. Notably, our analyses revealed that in contrast to the other cohorts, nearly all resistant tumours after chronic olaparib treatment (cohort 4) correlated with reduced mRNA expression of SHLD1 C20orf196 , SHLD2 FAM35A , 53BP1 and/or PARP1 ( Fig. 7a ; each heatmap column represents one tumour/mouse sample). Because this tumour model is polyclonal 40 , our data suggested that olaparib resistance mechanisms might arise through parallel evolutionary trajectories converging on loss of Shieldin activity. Furthermore, when we stratified a cohort of BRCA1-deficient PDX tumours by SHLD1/2 expression, ensuing analyses indicated that low SHLD1 C20orf196 transcript levels correlated with intrinsic olaparib resistance ( Fig. 7b ). One of the olaparib-resistant models (PDX127) demonstrated concomitant loss of both SHLD1 C20orf196 and SHLD2 FAM35A , while two other resistant models exhibiting normal SHLD1/2 transcript levels harboured deleterious 53BP1 mutations. Notably, several of these resistant PDX models also display BRCA1 nuclear foci 41 , suggesting the presence of multiple mechanisms of resistance, due to tumour heterogeneity and/or mechanistic cooperation. Supplementary Table 5 . All immunoblots are representative of two independent experiments; unprocessed scans of immunoblots are shown in Supplementary Fig. 8 .
Finally, we found that in contrast to 53BP1 deficiency 42 , SHLD1 C20orf196 or SHLD2 FAM35A loss increased the sensitivity of BRCA1proficient and BRCA1-null cells to IR, and even more markedly enhanced their sensitivity to the DNA crosslinking agent cisplatin (Fig. 7c,d and Supplementary Fig. 7b,c) . Furthermore, enhanced cisplatin sensitivity following SHLD1 C20orf196 or SHLD2 FAM35A inactivation was associated with increased DNA-damage focus formation by the FANCD2 protein that is involved in the detection and repair of DNA crosslinks ( Fig. 7e and Supplementary Fig. 7d ). These findings therefore suggested that, if loss/reduced expression of SHLD1/2 occurs in patients, it may provide collateral therapeutic vulnerabilities that could be exploited clinically. Supplementary Table 5 .
Discussion
Over the past two decades, it has become evident that eukaryotic cells have evolved multiple mechanisms of DNA DSB repair that are regulated in complex and sophisticated ways to optimize genome stability. In particular, much attention has focused on how cells strategically employ the two prime modes of DSB repair-NHEJ and HR-which antagonize one another, operate optimally in different contexts and whose relative usage is regulated by factors such as chromatin structure and cell-cycle stage. In addition to being of academic interest, work on such subjects is also of clinical relevance, . Predicted 3D structure of wild-type FAM35A with W489 and W640 positions (lower left). FAM35A W489/W640 promote efficient ssDNA binding in cellular extracts (lower right). b, Alignment of yRPA1 with FAM35A C terminus; amino acids critical for yRPA1 ssDNA binding and the corresponding amino acid residues in FAM35A are boxed. c, EMSAs on native (non-denaturing) gels with 10 nM ssDNA or dsDNA, and the indicated purified, bacterially expressed FAM35A C terminus or W489/W640A mutant (in µ M). d, Inducible GFP-FAM35A W489/W640A fails to efficiently form IRIF (12 h after 5 Gy of IR). Scale bar, 10 µ m. Representative images from three independent experiments. e, FAM35Ako RPE1 cells complemented with FAM35A derivatives in clonogenic survival assays. Right, AUC. f, Overexpression of FAM35A N terminus but not the C terminus or full-length FAM35A sensitizes wild-type cells to IR in clonogenic assays. Right, AUC. In e,f, bars represent mean ± s.e.m., one-way ANOVA; *P < 0.05, **P < 0.01, ***P < 0.001; NS, not significant (P ≥ 0.05); n = 3 independent experiments except Groups 2 and 4 in e (n = 2). Individual data points are plotted over bars; statistical source data including precise P values are provided in Supplementary Table 5 . All immunoblots are representative of two independent experiments; unprocessed scans of immunoblots are shown in Supplementary Fig. 8 . Supplementary Fig. 6e ). Scale bar, 10 µ m. e, HR assay in U2OS-TLR cells treated with indicated siRNAs (for gating strategy see Supplementary Fig. 6f ). Bars represent mean ± s.e.m., one-way ANOVA; n = 4 independent experiments. Individual data points are plotted over bars. f, Formation of spontaneous chromosomal aberrations in BRCA1ko cells is alleviated by FAM35A/C20orf196 inactivation. Representative images of metaphase spreads are shown and quantified; bars represent means, n = 2 independent experiments except FAM35Ako and C20orf196ko (n = 1). Individual data points are plotted over bars. g, Olaparib clonogenic survival assay with indicated RPE1ko and complemented cell lines. Bars represent mean ± s.e.m., one-way ANOVA; n = 4 independent experiments, except Groups 4 and 5 (n = 3) and Group 3 (n = 2); AUC is shown in Supplementary Fig. 6g . For a-c,e, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; NS, not significant (P ≥ 0.05); statistical source data including precise P values are provided in Supplementary Table 5 . Supplementary Fig. 7b,c, respectively) . Data shown represent mean ± s.e.m. (n = 3 independent experiments except for Group 7 in c and Group 7 in d where n = 2). e, Loss of FAM35A/C20orf196 leads to increased cisplatin-induced FANCD2 foci. Bars represent mean ± s.e.m., one-way ANOVA; ***P < 0.001, ****P < 0.0001; NS, not significant (P ≥ 0.05); n = 4 independent experiments, with individual data points plotted over bars; statistical source data are provided in Supplementary Table 5 . Scale bar, 10 µ m. f, Proposed model for the action of SHLD1/2 in DSB repair in the presence or absence of functional BRCA1.
resistance screens, we have uncovered two, previously uncharacterized proteins-SHLD1 C20orf196 and SHLD2 FAM35A -whose loss mediates PARP-inhibitor resistance and which we have shown act as the most distal factors of the 53BP1/RIF1/MAD2L2 molecular axis to promote NHEJ and restrict HR in BRCA1-deficient settings. Our screens have also identified additional candidate PARP-inhibitor resistance factors that await validation in future studies. Mechanistically, we have shown that SHLD1 C20orf196 and SHLD2 FAM35A form a complex, termed 'Shieldin' , with SHLD1 C20orf196 recruitment to DNA-damage sites via its interactions with SHLD2 FAM35A and other factors, and SHLD2 FAM35A interacting with single-stranded DNA via its C-terminal OB fold region. Moreover, we have established that SHLD1 C20orf196 and SHLD2 FAM35A promote NHEJ in a manner that may be mediated via their effects on restricting DNA-end resection, and serve as a barrier to HR by antagonizing the replacement of RPA with BRCA2/RAD51 on resected ssDNA in a manner counteracted by BRCA1. Our work is in line with a recent report 43 that independently identified SHLD1 C20orf196 and SHLD2 FAM35A as NHEJ-promoting factors and antagonists of HR in BRCA1-defective cells. This study also identified a third component, RINN1/SHLD3 CTC-534A2.2 , which is proposed to serve as a molecular bridge from RIF1 to MAD2L2 and SHLD1/2.
Although it seems possible that Shieldin loss contributes to HR restoration in BRCA1-deficient cells through effects on both resection and BRCA2/RAD51 loading, the relative importance of these mechanisms needs further investigation. We note that more extensive and possibly faster resection in the absence of Shieldin might enhance BRCA2/RAD51 loading. Alternatively, or in addition, Shieldin might serve as a physical barrier to BRCA2/RAD51 loading at dsDNA/ssDNA junctions in BRCA1-deficient cells-perhaps through it being tethered to DSB-flanking chromatin via the 53BP1/ RIF1/MAD2L2 complex allowing interactions between the C terminus of distal SHLD2 FAM35A and ssDNA (see Fig. 7f for a model and Supplementary Fig. 7e for SHLD2 FAM35A domain function summary). Nevertheless, we found that overexpression of the SHLD2 FAM35A N terminus but not the C terminus confers olaparib hypersensitivity to BRCA1/FAM35A double knockout cells, suggesting that at least in this context, chromatin binding by SHLD2 FAM35A plays a dominant role in restricting HR. By contrast, we found that both the SHLD2 FAM35A N and C termini are important for IR resistance (in BRCA1-proficient cells). As IR sensitivity in Shieldin-deficient cells probably reflects impaired NHEJ, we speculate that Shieldin potentiates NHEJ by restricting DSB resection as well as by assembling with other NHEJ-promoting factors to tether DSB ends together to facilitate their juxtaposition and repair.
Notably, we have found that SHLD1 C20orf196 or SHLD2 FAM35A inactivation confers enhanced cisplatin sensitivity to BRCA1-null or BRCA1-proficient cells. Such sensitivity probably does not reflect the roles for Shieldin in promoting NHEJ, restricting DNA-end resection or antagonizing BRCA1-mediated BRCA2/RAD51 loading because, in our hands, 53BP1 loss does not have pronounced effects on cisplatin sensitivity. Intra-strand DNA crosslinks (ICLs) generated by cisplatin and other compounds are detected and repaired by the Fanconi anaemia (FA) pathway, with a key FA protein being FANCD2, which forms foci at sites of these lesions 44 . We have observed that, following cisplatin treatment, FANCD2 foci were more pronounced in cells in which SHLD1 C20orf196 or SHLD2 FAM35A was inactivated. It will thus be of interest to determine if Shieldin-like MAD2L2, which (with REV3L) functions as a regulatory subunit of the trans-lesion DNA synthesis (TLS) polymerase Pol zeta, and whose biallelic inactivation has been associated with FA 45-47 -might also promote ICL repair via TLS mechanisms.
Finally, based on our findings, it will be interesting to evaluate SHLD1/2 expression in tumour biopsies from patients, establish whether this information can be used in patient stratification for PARP-inhibitor therapies, and determine whether SHLD1/2 expression changes arise in patients whose BRCA1-deficient cancers develop resistance after PARP-inhibitor treatment. In this regard, we note that if downregulation of Shieldin components in BRCA1-deficient cancers does confer clinical resistance, this might allow alternative treatments, such as ones based on platinum compounds.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41556-018-0140-1.
Methods CRISPR-Cas9 screen. CRISPR-Cas9 was performed using genome-scale (GeCKO) v2.0 20 . SUM149PT cells were transduced at a multiplicity of infection of 0.3 and 250-fold coverage of the library. Cells were then selected with puromycin for 7 days before treatment with three different PARPi (PARP inhibitor) for a further 14 days. ICs used were Olaparib IC95-2 μ M, BMN673 IC95-5 nM, AZD2461 IC70-4 µ M. Surviving clones from each condition were collected, and genomic DNA (gDNA) was isolated (Blood & Cell Culture DNA Midi Kit, Qiagen) and subjected to PCR with Illumina-compatible primers, followed by Illumina sequencing. Genes enriched or depleted in the inhibitor-treated samples were determined with software package MAGeCK version 0.5.5 (see commands in the Code availability section).
Cell culture. U2OS, U2OS-derived, HEK293 and HEK293T-LentiX cells were cultured as in ref. 39 . RPE1 p53 null FRT 48 and RPE1 p53 null FRT-derived cells were cultured in F12 (Ham's F12; Sigma-Aldrich) supplemented with 17 ml NaHCO 3 7.5% per 500 ml (Sigma-Aldrich). All media were supplemented with 10% (vol/vol) fetal bovine serum (FBS; BioSera), 100 U ml −1 penicillin, 100 µ g ml −1 streptomycin (Sigma-Aldrich) and 2 mM l-glutamine. SUM149PT cells were cultured in Ham's F12 Nutrient Mixture (ThermoFisher) supplemented with 5% (vol/vol) FBS (BioSera), 10 mM HEPES, 1 μ g ml −1 hydrocortisone, 5 μ g ml −1 insulin, and antibiotic as described above. For maintenance and selection of RPE1 FRT p53 null or U20S Trex cells stably expressing GFP or GFP-tagged constructs, 2 μ g ml −1 blasticidin (Sigma-Aldrich) and 0.5 mg ml −1 G418 (Invitrogen) were used. U2OS-TLR were cultured as in ref. 39 . In addition to RPE1 p53 null FRT-derived cells, U20S Trex cells stably expressing inducible constructs were cultured with 1 µ g ml −1 doxycycline (Sigma-Aldrich) for 24-48 h to induce expression of GFP constructs. All cells were originally obtained from the ATCC cell repository and routinely tested to be mycoplasma free. The U2OS and RPE1 cell lines were recently authenticated using Affymetrix SNP6 copy number analysis. Trf2 −/− ;p53 −/− ;TRF2(Ile468Ala) MEFs (TRF2ts MEFs) were as described previously 33, 49 . CH12F3 (CH12) 29 and CH12-Cas9 cell lines were cultured in RPMI 1640 supplemented with 10% FBS, 100 U ml −1 penicillin, 100 μ g ml −1 streptomycin, 50 µ M 2-mercaptoethanol, 1× MEM nonessential amino acids, 1 mM sodium pyruvate and 10 mM HEPES.
Generation of human stable cell lines and knockouts. U2OS Trex or RPE1
p53 null FRT-derived cells stably expressing inducible GFP-tagged constructs were generated by transfection of pcDNA5/FRT/TO-neo containing the GFPtagged construct and pOG44 (1:4, respectively). Selection began at 48 h using 0.5 mg ml −1 G418 (Invitrogen). Knockouts were generated in RPE1 p53 null cells by transfecting an ' All-in-one' plasmid 48 . Single-cell sorting by GFP expression was done using MoFlo (Beckman Coulter). Single clones were expanded, genomic DNA extracted and screened by PCR, TOPO-cloning and sequencing. Validated mouse embryonic stem cell (mESC) knockouts of Fam35a and C20orf196 were obtained from Haplobank (www.haplobank.at). Supplementary Table 3 . siRNA and plasmid transfection. siRNAs were obtained from MWG or IDT and transfected using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's protocol. Plasmid transfections were carried out using TransIT-LT1 (Mirus Bio) according to the manufacturer's protocol. For siRNA and DNA co-transfections, plasmids were transfected 8 h after siRNA treatment. See Supplementary Table 4 .
Plasmids and cloning. See
Random plasmid integration assay. The assay was performed as described in ref. 27 .
DNA-damage induction using chemical agents, ionizing radiation and laser micro-irradiation.
These processes were performed as described in ref. 39 .
FRAP and association kinetics. FRAP (fluorescence recovery after photobleaching) and association kinetics were performed as described in ref. 50 . TLR assays. The TLR assay and the constructs used herein are described in detail in refs 38, 39 .
Cell cycle profiling. Cell cycle profiling was performed as described in ref. 39 .
Clonogenic survival assays. Survival assays were performed as described in refs 27, 39 .
Whole cell extracts and immunoblotting. Whole cell extracts and immunoblotting were performed as described in ref. 39 . For detection of phospho-RPA (pS4/S8-RPA2), lysates were prepared by scraping cells in 2× SDS buffer followed by SDS-PAGE using 4-12% Bis-Tris gel (Invitrogen), and immunoblotting was carried out using SuperSignal West Pico PLUS (Thermo Scientific). IRDye800CW-and IRDye680-labelled secondary antibody were used for detection on an Odyssey infrared imager (LI-COR). Quantification of blots was performed using ImageJ. All protein concentrations were determined using a BCA assay (Pierce). All antibodies are listed in Supplementary Table 2 .
Immunoprecipitation. All immunoprecipitation procedures were performed twice as described in ref. 39 . For the co-immunoprecipitation shown in Fig. 2d  (FAM35A) , 293T cells were co-transfected with pMSCV-blas-eGFP-MAD2L2 and either pLX304-blast-V5-Empty or pLX304-V5-FAM35A. At 72 h post-transfection, cells were exposed to 25 Gy IR followed by 3 h recovery. GFP-Trap_MA beads (ChromoTek) were used, and immunoprecipitation was performed according to the manufacturer's protocol. For C20orf196 ( Supplementary Fig. 2c ), 293T cells were co-transfected with pMSCV-blas-3xFlag-hMAD2L2 and either pcDNA5.1-GFP or pcDNA5.1-GFP-C20orf196. At 72 h post-transfection, cells were exposed to 25 Gy IR followed by 3 h recovery. After washing with cold PBS, cells were lysed in 1 ml lysis buffer (50 mM Tris HCl pH 7.4; 150 mM NaCl; 1 mM EDTA; 1% Triton X-100) supplemented with the same inhibitors as above. After 30 min incubation on ice followed by centrifugation (16,000g) , anti-Flag M2 Magnetic Beads (M8823, Sigma-Aldrich) pre-washed with TBS (50 mM Tris HCl, 150 mM NaCl pH 7.4), were added to the lysate and rotated overnight at 4 °C. Immune complexes were eluted by 5 min boiling.
DNA pulldown experiments. Procedures are described in detail in ref. 39 , using oligos with the sequence: 5′ B io sG /A TC GC AT TG GC AT TG GC AA TG CG AT AC GA CT GA TC GA GG-GT AC TC AG CT AG CT GA TT CC GATCGGCTTATTCCGTGTACATACATCG GAT-3′ ( ID T).
In vitro GST pulldown. Gluathione sepharose beads (GE Healthcare) were washed with ice-cold PBS and blocked for 30 min with PBS supplemented with 10% bacterial lysate (non-induced BL21 cells, lysed using PBS/lysozyme) then resuspended in binding buffer (10 mM Tris pH 7.5, 150 mM NaCl, 0.5% NP40, 0.5 mM EDTA, 0.5% BSA). Purified GST (glutathione-S-transferase, bacterial expression), GST-FAM35A (Novus Biologicals) and His-C20orf196 (Creative BioMart) were added to the beads at 2 pmol and incubated for 30 min at 4 °C. Beads were washed five times with 10 mM Tris, pH 7.5, 250 mM NaCl, 0.5% NP40, 0.5 mM EDTA and eluted with 100 mM Tris pH 8, 20 mM reduced glutathione, 120 mM NaCl for 15 min rotating at 4 °C. The eluates were boiled for 5 min, loaded on 4-12% Bis-Tris gel (Invitrogen) and subjected to western blotting. The blots were probed with the indicated antibodies.
Recombinant protein purifications and electrophoretic mobility shift assays.
Wild-type and mutant FAM35A C-terminal domains were purified using the same method. Harvested cells were lysed by sonication in 50 mM Tris pH 8.0, 5% glycerol, 150 mM NaCl, 2 mM β -mercaptoethanol, 10 mM imidazole, protease inhibitor (Roche) and 40 g ml −1 deoxyribonuclease I (Sigma). After centrifugation at 30,000g for 30 min, supernatant was loaded onto a gravity column containing Ni-NTA affinity resin (Qiagen) pre-equilibrated with 50 mM Tris pH 8.0, 5% glycerol, 150 mM NaCl, 2 mM β -mercaptoethanol and 10 mM imidazole. After washing beads with the same buffer for 10× column volume, protein was eluted using 50 mM Tris pH 8.0, 5% glycerol, 150 mM NaCl, 2 mM β -mercaptoethanol and 100 mM imidazole. The eluate was dialysed with Q column (GE healthcare) buffer A (20 mM Tris pH 8.0, 50 mM NaCl, 5% glycerol and 2 mM β -mercaptoethanol) and loaded onto a 5 ml Q column. Protein was eluted in a gradient against buffer B (20 mM Tris pH 8.0, 1 M NaCl, 5% glycerol and 2 mM β -mercaptoethanol). Fractions containing FAM35A protein were collected and further purified by running through a Superdex 200 10/300 column (GE Healthcare) equilibrated in buffer GF (gel-filtration, 20 mM Tris pH 8, 150 mM NaCl, 5% glycerol and 5 mM dithiothreitol). Protein samples during each step of purification were analysed on 4-12% Bis-Tris gels (Invitrogen). Final purified samples were concentrated and stored at − 80 °C. Both forward and reverse 90-base DNA oligos (IDT) (F: 6-FAM (6-carboxyfluorescein)-ATCGC ATTGGCATTGGCAATGCGATACGACTGATCGAGGGTACTCAGCTAG CTGATTCCGATCGGCTTATTCCGTGTACATACATCGGAT; R:6-FAM-ATCCGATGTATGTACACGGAATAAGCCGATCGGAATCAGCTAGCT GAGTACCCTCGATCAGTCGTATCGCATTGCCAATGCCAATGCGAT) were dissolved in annealing buffer (10 mM Tris pH 8.0, 50 mM NaCl and 1 mM EDTA) to a final concentration of 100 μ M. DNA oligo F was used as ssDNA for electrophoretic mobility shift assay (EMSA). Equal volumes of DNA oligo F and R were mixed and annealed (heated to 95 °C for 2 min and cooled to 25 °C over 45 min) to generate dsDNA. Each 20 μ l of EMSA reaction contained 10 nM of ssDNA/dsDNA incubated with different concentrations of proteins in 20 mM Tris HCl pH 7.5, 50 mM KCl, 5% (vol/vol) glycerol, 100 μ M dithiothreitol, 10 μ g ml −1 BSA. Samples were incubated at 37 °C for 15 min and applied onto a 5% polyacrylamide native gel in 0.5× TBE buffer for electrophoresis at 4 °C. DNA was visualized by Typhoon 9000 (GE Healthcare).
GFP-Trap pulldown for mass spectrometry. HEK293T cells were cultured in SILAC medium containing either l-arginine and l-lysine, or l-arginine [ 13 C 6 , 15 N 4 ] and l-lysine [ 13 C 6 , 15 N 2 ] (Cambridge Isotope Laboratories) as described previously 51 . Cells were lysed 48 h post-transfection in modified RIPA buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.1% sodium deoxycholate) supplemented with protease, phosphatase inhibitors and Nethylmaleimide. Lysates were cleared by centrifugation at 16,000g for 15 min at 4 °C and protein concentrations were estimated using QuickStart Bradford Protein assay (BioRad). Per SILAC condition, 20 µ l of pre-equilibrated GFP-Trap-A beads (ChromoTek) were added to 2 mg of lysate and incubated 1 h at 4 °C while rotating, followed by three washes with modified RIPA buffer. Bound proteins were eluted in NuPAGE LDS Sample Buffer (Life Technologies) supplemented with 1 mM dithiothreitol, heated at 70 °C for 10 min and alkylated with 5.5 mM chloroacetamide at RT. Samples were loaded onto 4-12% gradient SDS-PAGE gels, and proteins were stained using a Colloidal Blue Staining Kit (Life Technologies) and digested in gel using trypsin. Peptides were extracted from the gel and desalted on reversed-phase C18 StageTips 52 .
Mass spectrometry analysis. Peptide fractions were analysed on a quadrupole Orbitrap mass spectrometer (Q Exactive Plus, Thermo Scientific) equipped with an EASY-nLC 1000 (Thermo Scientific) as described in ref. 53 . Peptide samples were loaded onto C18 reversed-phase columns and eluted with a linear gradient from 8 to 40% acetonitrile containing 0.1% formic acid for 2 h. The mass spectrometer was operated in data-dependent mode, automatically switching between MS and MS2 acquisition. Survey full-scan MS spectra (m/z 300-1,650) were acquired in the Orbitrap. The ten most intense ions were sequentially isolated and fragmented using HCD (higher-energy C-trap dissociation) 54 . Fragment spectra were acquired in the Orbitrap mass analyser. Raw data files were analysed using MaxQuant (development version 1.5.2.8) 55 . Parent ion and MS2 spectra were searched against a database containing 92,578 human protein sequences obtained from UniProtKB, released in December 2016, using the Andromeda search engine 56 . Spectra were searched with a mass tolerance of 6 ppm in the MS mode, 20 ppm in HCD MS2 mode, strict trypsin specificity and allowing up to three miscleavages. Cysteine carbamidomethylation was searched as a fixed modification, whereas protein N-terminal acetylation, methionine oxidation, N-ethylmaleimide modification of cysteines were searched as variable modifications. The data set was filtered based on posterior error probability to arrive at a false discovery rate below 1% estimated using a target-decoy approach 57 .
Immunofluorescence and microscopy imaging. Confocal imaging for γ H2AX, RAD51, RPA, ssDNA (BrdU), BLM, BRCA2, FANCD2, Cyclin A and GFP (FAM35A and C20orf196) was performed as described in ref. 39 ; for RAD51 and Cyclin A the pre-extraction step was omitted and cells were permeabilized for 15 min in 0.2% Triton X-100 (Sigma) in PBS after fixation. Super-resolution images were acquired using a Deltavision OMX 3D-SIM System V3 BLAZE (Applied Precision, a GE Healthcare company) equipped with three sCMOS (scientific complementary metal-oxide semiconductor) cameras, 405, 488 and 592.5 nm diode laser illumination, an Olympus Plan Apo N × 60, 1.42 NA oil objective, and standard excitation and emission filter sets. Imaging of each channel was done sequentially using three angles and five phase shifts of the illumination pattern, as described in ref. 58 . Sections were acquired at 0.125 μ m z steps. Raw OMX data were reconstructed and channel registered in SoftWoRx software version 6.5.2 (Applied Precision, a GE Healthcare company). Voxelwise nearest-neighbour distances were measured for the GFP-FAM35A signal relative to the 53BP1 signal using a custom script (Butler R) for Fiji (https://github.com/gurdon-institute/OMX-Spatial-Analysis). The script maps signal volumes using Kapur's maximum entropy thresholding method 59 and measures distances using the exact signed 3D Euclidean distance transform with internal distances set to zero for display on the histogram. For all images, scale bars represent 10 μ m.
Multiplex fluorescence in situ hybridization. Human 24-colour multiplex fluorescence in situ hybridization (M-FISH) probe preparation and slide treatment was carried out as in ref. 60 . For each human cell sample, 10-30 metaphases were karyotyped based on the M-FISH classification and DAPI-banding pattern. FISH on metaphase spreads using BAC probes was performed as previously described 61 and counted manually. For CSR assays, DNA FISH on metaphase spreads was performed as previously described 61 and counted manually. At least 470 metaphases were evaluated per genotype, using at least two independent clones for each condition. For telomere uncapping, cell harvesting, preparation of metaphase spreads and telomere FISH with an Alexa488-(CCCTAA repeat) peptide nucleic acid custom probe (PN-TC060-005, Panagene/Eurogentec), metaphase chromosome analysis was done as described previously 6 . The data represent two independent experiments, with ≥ 1,300 chromosomes for each condition, counted manually after blinding the genotypes.
Telomere fusion assays and MEFs viral transduction. Cells were transduced as in ref. 49 with pLKO-puro shRNA lentiviruses obtained from the MISSION shRNA library (Sigma), against mouse genes as described or left untransduced ('empty'). For assessment of telomere NHEJ, TRF2ts MEFs were grown for 24 h at the nonpermissive temperature of 39 °C to inactivate TRF2 and induce NHEJ-dependent chromosome end-to-end fusions because of telomere uncapping.
CSR assays for CH12 and CH12-Cas9 cell lines. The CH12-Cas9 cell line was generated by transducing CH12-Cas9 cells made using spin-infect with lentivirus particles packaged in HEK293T. Plasmids: pKLV2-EF1aBsd2Acas9-W, pxPAX2 (Addgene #12260), VSV-G and pMD2.G (Addgene #12259). Blasticidin selection (10 μ g ml −1 ) started 48 h after transduction for one week. In sgRNA expression plasmids for CSR assays, sgRNAs were used to target Fam35a, C20orf196 and Mad2l2/Rev7 mouse genes (two sgRNAs per target gene; sequences listed in Supplementary Table 4 ). sgRNAs were cloned into pKLV-flipped U6gRNA_ CCDB_PB_BbsI_PGKpuro2ABFP vector 62 . For the generation of wild-type and knockout CH12-Cas9 cell clones, 53bp1 null CH12 cell clones (gift from F. Alt) were as previously described 63 . 12 million CH12-Cas9 cells were nucleofected with 2.2 μ g each of sgRNA-1 and sgRNA-2 and 0.6 μ g of piggyBac transposase expression vector 64 , using an Amaxa Nucleofector, Nucleofector Kit V solution (Lonza) and program X-001. Two days later, BFP-positive/puromycin-resistant CH12-Cas9 cells were selected with 3 μ g ml −1 puromycin for one week. Cells were then single cell diluted into 96-well plates, further cultured and screened by PCR, and Sanger sequenced using PCR primers (listed in Supplementary Table 4) . For CSR and cell proliferation assays, CH12 cells were plated at 50,000 cells per ml in complete RPMI supplemented with anti-CD40 antibody (1 μ g ml −1 , Miltenyi), IL-4 (20 ng ml −1 , Miltenyi) and TGF-β (1 ng ml −1 , R&D Biotech) to induce IgM to IgA switching. After 3 days, cells were assayed for class-switching by flow cytometry using an IgA-PE antibody (eBiosciences) and a Canto II analyser (BD Biosciences). Viable cells were counted using a Casy cell counter (Roche). CSR and proliferation assays were done on 3× wild-type (WT), 3× Fam35a knockout (Fam35a), 3× C20orf196 knockout (C20orf196), 2× 53bp1 knockout (53bp1) and 3× Mad2l2 knockout (Mad2l2) cell lines in three independent experiments. For RT-PCR analysis, Igh, α germ-line transcripts (αGLT) and Aid mRNA were quantified as previously described 12 . Primers are listed in Supplementary Table 4 .
Patient-derived tumour xenografts. PDXs were generated and established from breast or ovarian cancer patients' samples (with consent) as previously described 40 . The research was done with appropriate approval by the National Research Ethics Service, Cambridgeshire 2 REC (REC reference number: 08/ H0308/178), and by the Vall d'Hebron Hospital Clinical Investigation Ethical Committee (PR(AG)183/2012). STG201, the PDX model used in this study, is a BRCA-null model featuring BRCA1 promoter methylation, loss of BRCA1 mRNA and protein expression. We have previously shown its sensitivity in vivo and in PDX-derived cells to PARP inhibitors, including olaparib. STG201 is also linked to deep molecular and drug sensitivity annotation 40 (http://caldaslab.cruk. cam.ac.uk/bcape/). All other PDXs were derived from breast or ovarian tumours from BRCA1-mutation carriers or BRCA1 epigenetic silencing due to promoter hypermethylation 41 . PDX127 did not show any co-expression of BRCA1 but it was low in both FAM35A and C20orf196 expression. None of the five PARPisensitive PDXs exhibited low levels of C20orf196, FAM35A or 53BP1 loss nor BRCA1 hypomorphs. The study was compliant with all relevant ethical regulations regarding research involving animal use and human participants.
Generation of acquired drug resistance in vivo. AZD2281 (Olaparib/Lynparza) as a PARP inhibitor was administered to immunocompromised tumour-bearing mice following randomization, as previously described (50 mg kg −1 , 5 days per week) 40 . To classify the response of the subcutaneous implants we modified the RECIST (response evaluation criteria in solid tumours) criteria to be based on the percent tumour volume change following continuous olaparib treatment: complete response (CR); best response, ≤ − 95%; partial response (PR), − 95% < best response ≤ − 30%; stable disease (SD), − 30% < best response ≤ + 20%; progressive disease (PD), % tumour volume change at day 21 of treatment > + 20%. PARPi-resistant PDXs exhibited PD while PARPi-sensitive models exhibited SD, PR or CR. For STG201, time-matched vehicle-and olaparib-treated samples were collected 25 days after treatment (PARPi naive PDX) and processed for RNA extractions and sequencing. A couple of mice in the study were left with continued exposure to olaparib until tumour regrowth. One of these resistant tumours was serially passaged 126 days after treatment into new host mice (PARPi-resistant PDX) and treated with further vehicle or olaparib. At 58 days after treatment, the resistance phenotype was confirmed and samples were collected and processed for RNA-sequencing. Growth curves show average and standard deviation of at least five independent tumour volumes per trial arm. All experimental procedures were approved by the University of Cambridge Animal Welfare and Ethical Review Committee and by the Vall d'Hebron Hospital Clinical Investigation Ethical Committee and Animal Use Committee. For RNA-sequencing, RNA was extracted from all samples using the Qiagen miRNeasy or RNeasy Mini kit (cat. ID 217004 or 74104) according to the manufacturer's instructions. Libraries for Illumina sequencing were prepared using a TruSeq Stranded mRNA HT kit or Total RNA Library Prep kit with Ribo-Zero Gold (cat. ID, RS-122-2103 or RS-122-2301, Illumina). 500 ng of total RNA with RNA integrity numbers (RINs) above 8 was used for library preparation. Samples were processed following the manufacturer's HS (High-Sample) instructions (part no. 15031048 Rev. E, Illumina) with 12 or 15 cycles of PCR used at the Enrichment of DNA Fragments step. All libraries were quantified using KAPA Library Quantification Kit Illumina ROX Low (Cat ID, KK4873, KAPA Biosystems) and normalized. Libraries were pooled in equal volumes and pools were used for clustering on a HiSeq4000 sequencing flow cell following the manufacturer's instructions. Sequencing was performed using 150 bp or 100 bp paired-end run types for dual-indexed libraries. Before alignment, the sequencing quality of the reads was enforced using Trim Galore! 1 nature research | reporting summary 
Data analysis
Above statistical parameters are indicated in the methods section. Graph display and statistical analysis was performed using Prism v7 for MacOs (GraphPad Software Inc., USA). ImageJ was used to quantify immunoblot bands (ImageJ 2.0.0). Flow cytometry analysis using Flowjo (BD Inc, USA). For RNA sequencing studies, prior to alignment, sequencing quality of the reads was enforced using Trim Galore! (v0.4.2). Reads were aligned to reference genomes using STAR (v2.5.2b). Counts were assigned to genome features using featureCounts(v1.5.2). Counts from multiple sequencing runs were merged/normalised using edgeR package. MaxQuant v1.5.2.8 was used for Mass Spectrometry data analysis. Raw OMX data was reconstructed and channel registered in SoftWoRx software version 6.5.2 (Applied Precision, a GE Healthcare company). FIJIv2.0.0 was used for OMX data analysis.
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